OCUTF (Ocumension Therapeutics) Moat Score: 0/10 (As of Jun. 25, 2026)


OCUTF Ocumension Therapeutics OCUTF
52 GF Score
Price $0.70
GF Value $2.99
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Ocumension Therapeutics Moat Score?

Ocumension Therapeutics has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Ocumension Therapeutics has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Ocumension Therapeutics might have No Moat - No discernible moat.

Ocumension Therapeutics  (OTCPK:OCUTF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Ocumension Therapeutics Moat Score Related Terms

OCUTF
52GF Score
Ocumension Therapeutics OCUTF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ocumension Therapeutics (OCUTF) Overvalued in 2026?

Based on GuruFocus' analysis, Ocumension Therapeutics stock appears to be undervalued. The current stock price of $0.70 is trading 76.6% below its estimated GF Value™ of $2.99. GuruFocus considers Ocumension Therapeutics to be Possible Value Trap.

Key valuation signals for OCUTF:

  • Moat Score: 0
  • GF Value™: $2.99 vs. price of $0.70 (76.6% below fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the OCUTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ocumension Therapeutics Business Description

Other Exchanges 01477:Hong Kong5DG:Germany
Address No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
52GF Score

Get the complete analysis for OCUTF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price
$2.99
GF Value